MASS (908 Devices) ROCE %: -17.17% (As of Mar. 2026)

What is 908 Devices ROCE %?

908 Devices MASS +2.87% 70 ROCE % is -17.17% as of Mar. 2026. GuruFocus rates MASS with a GF Score™ of 70/100 and a GF Value™ of $6.91 (Modestly Overvalued). The stock has 9 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. 908 Devices's annualized ROCE % for the quarter that ended in Mar. 2026 was -17.17%.

908 Devices (NAS:MASS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

908 Devices ROCE % Related Terms

908 Devices ROCE % Historical Data

* Premium members only.

The historical data trend for 908 Devices's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

908 Devices ROCE % Chart

908 Devices Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-10.47

-14.24

-18.03

-19.03

-17.69

908 Devices Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-21.95	-19.78	-14.43	-8.29	-17.17

70GF Score

908 Devices Inc MASS

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

908 Devices ROCE % Calculation

908 Devices's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-25.68	/	( ( (159.476 - 25.149)	+	(190.071 - 34.064) )	/ 2 )
	=	-25.68	/	( (134.327	+	156.007)	/ 2 )
	=	-25.68	/	145.167
	=	-17.69 %

908 Devices's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-26.012	/	( ( (190.071 - 34.064)	+	(186.695 - 39.66) )	/ 2 )
	=	-26.012	/	( ( 156.007	+	147.035 )	/ 2 )
	=	-26.012	/	151.521
	=	-17.17 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -17.17% mean?

908 Devices (MASS) has a ROCE % of -17.17% as of Mar. 2026.

Is 908 Devices' ROCE % too high?

908 Devices' current ROCE % is -17.17%. Overall, 908 Devices has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does 908 Devices' ROCE % compare to ELMD and SI?

908 Devices' ROCE % of -17.17% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 908 Devices's current ROCE % is -17.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is 908 Devices stock overvalued right now?

Based on GuruFocus' analysis, 908 Devices (MASS) is currently considered Modestly Overvalued. The stock's GF Value™ is $6.91, compared to a current price of $8.98 — trading 30% above its estimated fair value. The current ROCE % is -17.17%. 908 Devices' overall GF Score™ is 70/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For 908 Devices (MASS), the current ROCE % is -17.17% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 908 Devices (MASS) Overvalued in 2026?

Based on GuruFocus' analysis, 908 Devices stock appears to be overvalued. The current stock price of $8.98 is trading 30% above its estimated GF Value™ of $6.91. GuruFocus considers 908 Devices to be Modestly Overvalued.

Key valuation signals for MASS:

ROCE %: -17.17%
GF Value™: $6.91 vs. price of $8.98 (30% above fair value)
GF Score™: 70/100 with 9 warning signs

No single metric tells the full story. See the MASS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

908 Devices Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies ELMD SI CV SENS DCTH SGHT OFIX VMD QSI CLPT ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA

Address 44 3rd Avenue, Burlington, MA, USA, 01803

Website https://www.908devices.com

908 Devices Inc develops a suite of purpose-built handheld devices for point-of-need chemical analysis. Leveraging mass spectrometry, optical spectroscopy, analytics and machine learning technologies, the company makes devices that are smaller and more accessible than conventional laboratory instruments. Its devices, including MX908, ThreatID, XplorIR and VipIR, are used to analyze unknown materials and provide actionable answers in health, safety and defense technology applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure and security threats. The company reimagines mass spectrometry technology by developing smaller, lower-cost and simpler-to-operate devices compared to conventional instruments, and generates maximum revenue from the United States.

70GF Score

Get the complete analysis for MASS

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.98

Price

$6.91

GF Value

View MASS Analysis

See ROCE % data for all stocks →